There is a demand in the market of products for liver health, therefore, Plameca has developed a formula that contains berberine and curcumin. There is existing evidence for those ingredients on their beneficial effect in non-alcoholic fatty liver diseases (NAFLD). In addition, the formula contains other traditionally used active ingredients with health benefits for the liver. The objective of the present work was a primary evaluation of the effects of the dietary supplement syrup Berdetox® on the prevention and the reversion of mild steatosis in the in vitro HepG2 cell model. HepG2 cells were incubated with a mixture of oleic acid and palmitic acid at a respective proportion of 2:1 and a final concentration of 0.25 mM for 24 h to induce steatosis. Cells were exposed to the test syrup 2 h prior and during lipid overload or after removal of the lipid mixture. The intracellular lipid content and the membrane integrity were determined by Nile red and neutral red staining, respectively. The effect of the metabolites of the active components of the syrup was assessed indirectly using the same experimental approach after previous incubation of the syrup with human hepatocytes. The lipid mixture effectively induced steatosis in the HepG2 cells. The intracellular lipid content was reduced dose dependently after simultaneous exposure to test syrup with or without previous incubation with human hepatocytes. However, the reversive effect of the syrup was of the same magnitude than the treatment with incubation medium only. The cell membrane integrity remained unaffected after lipid overload and after the treatment with the test syrup or its excipients. Berdetox® demonstrated a preventive effect against steatosis in HepG2 cells as measured by the reduction of the intracellular lipid content in vitro at in vivo meaningful concentrations of its marker ingredients. The experimental conditions used in this work were based in the induction of mild steatosis as a response to cell overload with a mixture of oleic and palmitic acids at a proportion considered to mimic the reversible initial phase of liver disease. The human hepatic metabolites of the active components showed also equivalent efficacy. The reversive effect of the test ingredients could not be demonstrated because steatosis was reverted by endogenous cell reparation mechanisms.
| Published in | World Journal of Food Science and Technology (Volume 6, Issue 2) |
| DOI | 10.11648/j.wjfst.20220602.14 |
| Page(s) | 47-57 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Berdetox®, Steatosis, HepG2, Berberine, Silymarin, Curcumin, Non-alcoholic Fatty Liver Diseases (NAFLD)
| [1] | Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, O’Connor J-E. A human hepatocellular in vitro model to investigate steatosis. Chemico-Biological Interactions 2007; 165: 106–116. |
| [2] | Müller FA, Sturla SJ. Human in vitro models of nonalcoholic fatty liver. Current Opinion in Toxicology 2019; 16: 9-16. |
| [3] | Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Hyponatremia and hypernatremia. Int J Environ Res Public Health 2019; 16: 4434–4460. |
| [4] | Moravcová A, Cervinkováma Z, Kucera O, Kucera O, Mezera V, Rychtrmoc D, Lotková H. The effect of oleic and palmitic acid on induction of steatosis and cytotoxicity on rat hepatocytes in primary culture. Physiol Res 2015; 64 (Suppl. 5): S627-S636. |
| [5] | Izdebska M, Piatkowska-Chmiel I, Korolczuk A, Herbet M, Gawronska-Grzywacz M, Gieroba R, et al. The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells. Can J Physiol Pharmacol 2017; 95: 1442-1453. |
| [6] | Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y. Hepatoprotective effects of chinese medicinal herbs: a focus on anti-inflammatory and anti-oxidative activities. Int J Mol Sci 2016; 17: 465-502. |
| [7] | Rafiei H, Omidian A, Bandy B. Dietary polyphenols protect against oleic acid-induced steatosis in an in vitro model of NAFLD by modulating lipid metabolism and improving mitochondrial function. Nutrients 2019; 11: 541-558. |
| [8] | Rafiei H, Omidian A, Bandy B. Comparison of dietary polyphenols for protection against molecular mechanisms underlying non-alcoholic fatty liver disease in a cell model of steatosis. Mol Nutr Food Res 61 (9). https://doi.org/10.1002/mnfr.201600781. |
| [9] | Lin Y, Ding D, Huang Q, Liu Q, Lu H, Lu Y, et al. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. Biochim Biophys Acta (BBA)-Molecular and Cell Biology of Lipids 2017; 1862: 869–882. |
| [10] | Bai X, Hong W, Cai P, Chen Y, Xu C, et al. Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis. Toxicol Appl Pharmacol 2017; 324: 12-25. |
| [11] | Zhao F, Xie P, Jiang J, Zhang L, An W, Zhan Y. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci 2014; 15: 4019-4030. |
| [12] | Canfrán-Duque A, Pastor O, Reina M, Lerma M, Cruz-Jentoft AJ, Lasunción MA, et al. Curcumin mitigates the intracellular lipid deposit induced by antipsychotics in vitro. PLoS One 2015; 10 (10): e0141829. |
| [13] | Stellavato A, Pirozzi AVA, De Novellis F, Scognamiglio I, Vassallo V, Giori AM, et al. In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model. Lipids in Health and Disease 2018; 17: 24-35. |
| [14] | Song Z, Song M, Lee DYW, Liu Y, Deaciuc YV, McClain CJ. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol 2007; 101: 262–268. |
| [15] | Test Guideline for the Testing of Chemicals. The Short Time Exposure In Vitro Test Method for Identifying Chemicals Inducing Serious Eye Damage and Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage. 26 June 2021, OECD 491 Test Guideline. https://www.oecd-ilibrary.org/docserver/ |
| [16] | Pappas A, Anthonavage A, Gordon JS. Metabolic fate and selective utilization of major fatty acids in human sebaceous gland. J Invest Dermatol 2002; 118: 164–171. |
| [17] | Repetto G, Del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nature Protocols 2008; 3: 1125–1131. |
| [18] | Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5: 109-113. |
| [19] | Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes. 2003; 52: 726–733. |
| [20] | Miller TA, LeBrasseur NK, Cote GM, Trucillo MP, Pimentel DR, Ido Y, et al. Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes, Biochem Biophys Res Commun. 2005; 336: 309–315. |
| [21] | Rafiei H, Omidian A, Bandy B. Phenolic breakdown products of cyanidin and quercetin contribute to protection against mitochondrial impairment and reactive oxygen species generation in an in vitro model of hepatocyte steatosis J Agric Food Chem 2019; 67: 6241−6247. |
| [22] | Bitensky L. The reversible activation of lysosomes in normal cells and the effect of pathological conditions. In: De Reuck, A. V. S, Cameron, M. P, editors. Lysosomes. Boston Little, Brown; 1963: 362–375. |
| [23] | Hu X, Zhang Y, Xue Y, Zhang Z, Wang J. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. Basic Clin Pharmacol Toxicol. 2007; 101: 262–268. |
| [24] | Stohs SJ, Chen O, Ray S. D, Ji J, Bucci LR, Preuss HG. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review. Molecules. 2020; 25: 1397-1409. |
| [25] | Xie Y, Zhang D, Zhang J, Yuan J. Metabolism, transport and drug–drug interactions of silymarin. Molecules. 2019; 24: 3693-3706. |
| [26] | Pandey A, Chaturvedi M, Mishra S, Kumar P, Somvanshi P, Chaturvedi R. Reductive metabolites of curcumin and their therapeutic effects. Heliyon. 2020; 6 (11): e05469. |
| [27] | Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Dug Metab Dispos. 2008; 36: 65-72. |
| [28] | Buchanan B, Meng Q, Poulin M-M, Zuccolo J, Azike CG, Gabriele J. Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. Plos One. 2018; March 26. On line: https://doi.org/10.1371/journal.pone.0194979 |
| [29] | Purpura M, Lowery RP, Wilson JM, Mannan H, Münch H, Razmovski-Naumovski V. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr. 2018; 57: 929–938. |
APA Style
Josep Sola, Josep Manuel Llabres, Alba Novella, Angel Menargues. (2022). In vitro Protective Effect of Berdetox® on Fatty Acid Induced Steatosis in HepG2 Cells. World Journal of Food Science and Technology, 6(2), 47-57. https://doi.org/10.11648/j.wjfst.20220602.14
ACS Style
Josep Sola; Josep Manuel Llabres; Alba Novella; Angel Menargues. In vitro Protective Effect of Berdetox® on Fatty Acid Induced Steatosis in HepG2 Cells. World J. Food Sci. Technol. 2022, 6(2), 47-57. doi: 10.11648/j.wjfst.20220602.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.wjfst.20220602.14,
author = {Josep Sola and Josep Manuel Llabres and Alba Novella and Angel Menargues},
title = {In vitro Protective Effect of Berdetox® on Fatty Acid Induced Steatosis in HepG2 Cells},
journal = {World Journal of Food Science and Technology},
volume = {6},
number = {2},
pages = {47-57},
doi = {10.11648/j.wjfst.20220602.14},
url = {https://doi.org/10.11648/j.wjfst.20220602.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjfst.20220602.14},
abstract = {There is a demand in the market of products for liver health, therefore, Plameca has developed a formula that contains berberine and curcumin. There is existing evidence for those ingredients on their beneficial effect in non-alcoholic fatty liver diseases (NAFLD). In addition, the formula contains other traditionally used active ingredients with health benefits for the liver. The objective of the present work was a primary evaluation of the effects of the dietary supplement syrup Berdetox® on the prevention and the reversion of mild steatosis in the in vitro HepG2 cell model. HepG2 cells were incubated with a mixture of oleic acid and palmitic acid at a respective proportion of 2:1 and a final concentration of 0.25 mM for 24 h to induce steatosis. Cells were exposed to the test syrup 2 h prior and during lipid overload or after removal of the lipid mixture. The intracellular lipid content and the membrane integrity were determined by Nile red and neutral red staining, respectively. The effect of the metabolites of the active components of the syrup was assessed indirectly using the same experimental approach after previous incubation of the syrup with human hepatocytes. The lipid mixture effectively induced steatosis in the HepG2 cells. The intracellular lipid content was reduced dose dependently after simultaneous exposure to test syrup with or without previous incubation with human hepatocytes. However, the reversive effect of the syrup was of the same magnitude than the treatment with incubation medium only. The cell membrane integrity remained unaffected after lipid overload and after the treatment with the test syrup or its excipients. Berdetox® demonstrated a preventive effect against steatosis in HepG2 cells as measured by the reduction of the intracellular lipid content in vitro at in vivo meaningful concentrations of its marker ingredients. The experimental conditions used in this work were based in the induction of mild steatosis as a response to cell overload with a mixture of oleic and palmitic acids at a proportion considered to mimic the reversible initial phase of liver disease. The human hepatic metabolites of the active components showed also equivalent efficacy. The reversive effect of the test ingredients could not be demonstrated because steatosis was reverted by endogenous cell reparation mechanisms.},
year = {2022}
}
TY - JOUR T1 - In vitro Protective Effect of Berdetox® on Fatty Acid Induced Steatosis in HepG2 Cells AU - Josep Sola AU - Josep Manuel Llabres AU - Alba Novella AU - Angel Menargues Y1 - 2022/06/21 PY - 2022 N1 - https://doi.org/10.11648/j.wjfst.20220602.14 DO - 10.11648/j.wjfst.20220602.14 T2 - World Journal of Food Science and Technology JF - World Journal of Food Science and Technology JO - World Journal of Food Science and Technology SP - 47 EP - 57 PB - Science Publishing Group SN - 2637-6024 UR - https://doi.org/10.11648/j.wjfst.20220602.14 AB - There is a demand in the market of products for liver health, therefore, Plameca has developed a formula that contains berberine and curcumin. There is existing evidence for those ingredients on their beneficial effect in non-alcoholic fatty liver diseases (NAFLD). In addition, the formula contains other traditionally used active ingredients with health benefits for the liver. The objective of the present work was a primary evaluation of the effects of the dietary supplement syrup Berdetox® on the prevention and the reversion of mild steatosis in the in vitro HepG2 cell model. HepG2 cells were incubated with a mixture of oleic acid and palmitic acid at a respective proportion of 2:1 and a final concentration of 0.25 mM for 24 h to induce steatosis. Cells were exposed to the test syrup 2 h prior and during lipid overload or after removal of the lipid mixture. The intracellular lipid content and the membrane integrity were determined by Nile red and neutral red staining, respectively. The effect of the metabolites of the active components of the syrup was assessed indirectly using the same experimental approach after previous incubation of the syrup with human hepatocytes. The lipid mixture effectively induced steatosis in the HepG2 cells. The intracellular lipid content was reduced dose dependently after simultaneous exposure to test syrup with or without previous incubation with human hepatocytes. However, the reversive effect of the syrup was of the same magnitude than the treatment with incubation medium only. The cell membrane integrity remained unaffected after lipid overload and after the treatment with the test syrup or its excipients. Berdetox® demonstrated a preventive effect against steatosis in HepG2 cells as measured by the reduction of the intracellular lipid content in vitro at in vivo meaningful concentrations of its marker ingredients. The experimental conditions used in this work were based in the induction of mild steatosis as a response to cell overload with a mixture of oleic and palmitic acids at a proportion considered to mimic the reversible initial phase of liver disease. The human hepatic metabolites of the active components showed also equivalent efficacy. The reversive effect of the test ingredients could not be demonstrated because steatosis was reverted by endogenous cell reparation mechanisms. VL - 6 IS - 2 ER -
Email: